Truist Securities Reiterates Buy on Genmab, Raises Price Target to $67

Benzinga · 4d ago
Truist Securities analyst Gregory Renza reiterates Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $45 to $67.